Cargando…
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
Over the last decade, the therapeutic scenario for advanced non-small-cell lung cancer (NSCLC) has undergone a major paradigm shift. Immune checkpoint inhibitors (ICIs) have shown a meaningful clinical and survival improvement in different settings of the disease. However, the real benefit of this t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454231/ https://www.ncbi.nlm.nih.gov/pubmed/37628803 http://dx.doi.org/10.3390/ijms241612622 |
_version_ | 1785096139925618688 |
---|---|
author | Bronte, Giuseppe Cosi, Donato Michele Magri, Chiara Frassoldati, Antonio Crinò, Lucio Calabrò, Luana |
author_facet | Bronte, Giuseppe Cosi, Donato Michele Magri, Chiara Frassoldati, Antonio Crinò, Lucio Calabrò, Luana |
author_sort | Bronte, Giuseppe |
collection | PubMed |
description | Over the last decade, the therapeutic scenario for advanced non-small-cell lung cancer (NSCLC) has undergone a major paradigm shift. Immune checkpoint inhibitors (ICIs) have shown a meaningful clinical and survival improvement in different settings of the disease. However, the real benefit of this therapeutic approach remains controversial in selected NSCLC subsets, such as those of the elderly with active brain metastases or oncogene-addicted mutations. This is mainly due to the exclusion or underrepresentation of these patient subpopulations in most pivotal phase III studies; this precludes the generalization of ICI efficacy in this context. Moreover, no predictive biomarkers of ICI response exist that can help with patient selection for this therapeutic approach. Here, we critically summarize the current state of ICI efficacy in the most common “special” NSCLC subpopulations. |
format | Online Article Text |
id | pubmed-10454231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104542312023-08-26 Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? Bronte, Giuseppe Cosi, Donato Michele Magri, Chiara Frassoldati, Antonio Crinò, Lucio Calabrò, Luana Int J Mol Sci Review Over the last decade, the therapeutic scenario for advanced non-small-cell lung cancer (NSCLC) has undergone a major paradigm shift. Immune checkpoint inhibitors (ICIs) have shown a meaningful clinical and survival improvement in different settings of the disease. However, the real benefit of this therapeutic approach remains controversial in selected NSCLC subsets, such as those of the elderly with active brain metastases or oncogene-addicted mutations. This is mainly due to the exclusion or underrepresentation of these patient subpopulations in most pivotal phase III studies; this precludes the generalization of ICI efficacy in this context. Moreover, no predictive biomarkers of ICI response exist that can help with patient selection for this therapeutic approach. Here, we critically summarize the current state of ICI efficacy in the most common “special” NSCLC subpopulations. MDPI 2023-08-09 /pmc/articles/PMC10454231/ /pubmed/37628803 http://dx.doi.org/10.3390/ijms241612622 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bronte, Giuseppe Cosi, Donato Michele Magri, Chiara Frassoldati, Antonio Crinò, Lucio Calabrò, Luana Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? |
title | Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? |
title_full | Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? |
title_fullStr | Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? |
title_full_unstemmed | Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? |
title_short | Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? |
title_sort | immune checkpoint inhibitors in “special” nsclc populations: a viable approach? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454231/ https://www.ncbi.nlm.nih.gov/pubmed/37628803 http://dx.doi.org/10.3390/ijms241612622 |
work_keys_str_mv | AT brontegiuseppe immunecheckpointinhibitorsinspecialnsclcpopulationsaviableapproach AT cosidonatomichele immunecheckpointinhibitorsinspecialnsclcpopulationsaviableapproach AT magrichiara immunecheckpointinhibitorsinspecialnsclcpopulationsaviableapproach AT frassoldatiantonio immunecheckpointinhibitorsinspecialnsclcpopulationsaviableapproach AT crinolucio immunecheckpointinhibitorsinspecialnsclcpopulationsaviableapproach AT calabroluana immunecheckpointinhibitorsinspecialnsclcpopulationsaviableapproach |